BAJAJ BROKING
Metropolis Healthcare Ltd has acquired Core Diagnostics for ₹246.83 crore. This move will enhance its advanced cancer testing capabilities and deepen its presence in northern and eastern India. Shares closed at ₹2,187, up by 2.39%.
Metropolis Healthcare Ltd has announced the acquisition of a 100% stake in Delhi-NCR-based Core Diagnostics for ₹246.83 crore. The acquisition, financed through 55% cash and 45% equity swap, is expected to strengthen Metropolis’ capabilities in advanced cancer testing and expand its presence in northern and eastern India.
Also read: Syngene International Block Deal: Biocon to Sell 2% Stake at ₹825 per Share
Transaction Value: ₹246.83 crore.
Funding Split: 55% cash and 45% equity swap.
Target Completion: Within 60 days.
Revenue Impact: Core Diagnostics reported revenue of ₹110 crore in FY 2023-24.
Strategic Benefits: Enhanced cancer testing capabilities and market expansion.
Also read: Vodafone Idea to Issue Shares Worth ₹1,980 Crore at 39% Premium
Founded in 2012, Core Diagnostics operates in over 200 cities in India and specialises in cancer diagnostics. Its NABL- and CAP-accredited labs are located in Gurugram, Hyderabad, and seven other locations. Offering over 1,300 high-end tests, Core Diagnostics primarily focuses on cancer and serves more than 6,000 speciality prescribers. The company reported a robust 22% revenue CAGR over the past three years.
Metric | Value |
Founded | 2012 |
Presence | 200 cities |
Accreditations | NABL, CAP |
FY 2023-24 Revenue | ₹110 crore |
Tests Offered | 1,300+ |
Specialist Prescribers | 6,000+ |
Cancer Specialists Served | 1,600+ |
The acquisition positions Metropolis to capitalise on the growing oncology market, which is projected to expand at a 17.5% CAGR between 2023 and 2028. Shares of Metropolis Healthcare Ltd gained 2.39%, closing at ₹2,187 on the BSE. The deal is expected to boost market share and revenue growth in the specialised diagnostics sector.
Metropolis Healthcare Ltd’s acquisition of Core Diagnostics is a strategic step to solidify its position in advanced cancer testing and expand its national footprint. With synergies expected to deliver long-term growth, this acquisition aligns with the company’s vision of strengthening its diagnostics capabilities.
Also read: Tata Motors To Increase Passenger Vehicle Prices By Up To 3% From January
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading